Alice joined Forbion in 2026 as a Fellow in the BioEconomy team.
Alice completed her DPhil in Oncology at the University of Oxford where she investigated cell therapies for pancreatic cancer.
During this time, she gained experience at several funds including Future Planet Capital, Osney Capital and Oxonian Ventures. She has since worked in strategy and business development at multiple Oxford-based startups. At NeoVac she worked on indication selection, mapping mRNA vaccine clinical trial landscapes. At Entelo Bio she performed commercial analysis of target candidates and managed strategic partnerships.
Alice also holds a BA in Biomedical Sciences from Oxford.
